TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04342221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT03981237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation with a pulsed Er:YAG laser
Description: The root canals and the pulp chamber are filled with NaOCl 3%. Per canal, the laser tip is placed above the root canal entrance and activated (frequency 20 Hz, pulse energy 20 mJ and pulse length 50 μs) for 30s. TThe canal is then rinsed with NaOCl using a 27G needle, followed by a second application of laser, identical to the first.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonically activated irrigation
Description: The root canals and the pulp chamber are filled with NaOCl 3%. An Irrisafe file, driven by an ultrasonic unit according to the manufacturers' instructions, is held at 1-3 mm from WL (precurved if canal is curved) and activated for 30 s. The canal is then rinsed with NaOCl using a 27G needle. This cycle is repeated three times (i.e. 3\*20s).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthograde root canal treatment
Description: After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthograde root canal treatment
Description: After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.
Study: NCT00439946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil
Description: rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crono Five ambulatory pump
Description: Used for administration of IV Remodulin (treprostinil)
Study: NCT03755804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously (SQ) or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously (SQ) or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously (SQ) or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Description: Given intravenously (IV)
Study: NCT03426085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 6 mg Solution for Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02268721

Intervention type: DEVICE
Group type: OTHER
Intervention: Tablet computer
Description: Patients receive a tablet computer upon discharge. The tablet can be used for ordering food for delivery three times a week from the hospital kitchen.
Study: NCT04363476

Intervention type: OTHER
Group type: OTHER
Intervention: SHRED Osteoarthritis program
Description: Combined exercise and education intervention
Study: NCT03755804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Measurements
Description: Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Measurements
Description: Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Measurements
Description: Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
Study: NCT02279680

Intervention type: DEVICE
Group type: OTHER
Intervention: Electroencephalography

Intervention type: DEVICE
Group type: OTHER
Intervention: Electroencephalography

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assesments

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological assesments
Study: NCT03551444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of DAA-based treatment
Description: * Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~* HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~* During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~* Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~* SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~* Virological failures and early discontinuations of therapy due to adverse events will be also registered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of DAA-based treatment
Description: * Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~* HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~* During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~* Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~* SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~* Virological failures and early discontinuations of therapy due to adverse events will be also registered.
Study: NCT03755804

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
Study: NCT02516969

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Radiation
Study: NCT03544333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
Study: NCT03820622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
Description: patients in the study group will be treated by the Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-Eluting Balloon (Bingo)
Description: patients in the study group will be treated by the Paclitaxel-Eluting Balloon (Bingo)
Study: NCT02301416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine/topiramate
Description: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low calorie diet
Description: The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.
Study: NCT03062540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
Study: NCT03238859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real cTBS
Description: This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS
Description: This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
Study: NCT03656679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pectoralis Blockade (PECs)
Description: Ten milliliters of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited between the pectoralis major and minor (PECs I) and 20 cc of 0.25% bupivacaine with 2.5mcg/ml epinephrine deposited between the pectoralis minor and serratus anterior muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Blockade
Description: 10cc of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited at two levels (T3 and T5) per side while in the sitting position.
Study: NCT02750540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir enema
Study: NCT04363476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHRED Osteoarthritis program
Description: Combined exercise and education intervention
Study: NCT03636633

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard respiratory physiotherapy
Description: Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques.
Study: NCT02750540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir enema

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir enema

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline enema

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline enema
Study: NCT01032304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdosteine
Description: One 300 mg capsule twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule twice a day
Study: NCT03636633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard respiratory physiotherapy and inspiratory muscle training
Description: Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques. Addition to that, threshold IMT device will be used for the training. Training intensity will set at 40% of the maximum inspiratory pressure.
Study: NCT03208153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive
Description: Coronary angiogram and revascularization if anatomically feasible

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative
Description: Conservative
Study: NCT01295437

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vypro II mesh
Description: partly absorbable mesh

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Premilene LP
Description: lightweight mesh

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Premilene mesh
Description: A conventional polypropylene mesh (82 g/m2)
Study: NCT01374503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0651
Description: single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single or multiple i.v. administration
Study: NCT01293656

Intervention type: OTHER
Intervention: No intervention.
Description: There is no study intervention. Participants will be treated locally per site standards.
Study: NCT03396263

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-personalised advice
Description: Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalised dietary advice for improved food choice based on standard population health guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online personalised advice
Description: Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face personalised advice
Description: Provision of face-to-face personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
Study: NCT03859583

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 4 tsp of cayenne in a breakfast omelette

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: breakfast omelette without cayenne pepper
Study: NCT02744404

Intervention type: DEVICE
Intervention: POC EID
Study: NCT02955043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral techniques
Description: Improve nighttime sleep: Participants will receive a modified form of cognitive-behavioral therapy for insomnia with a primary focus on stimulus control, a set of techniques to strengthen the association between bed and sleep and weaken its association with stimulating behaviors.~Increase daytime activity: Participants will receive instruction in activity management strategies including prioritizing activities, planning activities during peak energy, activity pacing, and alternating between rest and activity. Participants will be provided with a basic step-count pedometer to enhance ability to self-monitor activity and increase motivation for activity.~The intervention will be adapted to individual needs based on assessments of sleep and activity patterns.
Study: NCT03583385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage XR (Test drug)
Description: Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage XR (Test drug)
Description: Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage XR (Comparator drug)
Description: Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage XR (Comparator drug)
Description: Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.
Study: NCT03690752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: unweighting using Alter-G Anti-Gravity Treadmill
Description: The unweighted group (experimental) is allowed to self-select a comfortable unweighting using the weight control feature on the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: normal weight using Alter-G Anti-Gravity Treadmill
Description: The weighted (control) group will walk at 100% their body weight using the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
Study: NCT03261427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica 150Mg Capsule
Description: 150 mg oral administered (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YNP-1807 330Mg Tablet
Description: 330 mg oral administered (QD)
Study: NCT02935439

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cell Phone
Description: Participants responded to questions about their heart failure symptoms using a cell phone.
Study: NCT03577730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate
Description: Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
Study: NCT01330108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ambrisentan
Description: ambrisentan 2.5mg, 5mg, \& 10mg. Daily dosage.
Study: NCT03577730

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose Water
Description: Prepared intravenous piggyback solutions of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants.
Study: NCT03976011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Laryngeal Ultrasonography
Description: TLU will be performed during the same time period of The gold standard NF (who is performed as usually after endocrine surgeries) by an investigator blind to the NF results, between D1 and D15.~The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments.
Study: NCT01160302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgranular Curcumin C3 Complex®
Description: 4 grams twice daily for 21-28 days
Study: NCT00953433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoflex tube
Description: Size decided upon gender.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyvinyl chloride endotracheal tube with a stylet
Description: Size decided upon gender.
Study: NCT00917696

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Iontophoresis and Laser Doppler with ATP
Description: Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Iontophoresis and Laser Doppler with Saline
Description: Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
Study: NCT03815513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brain MRI
Description: both case and control groups received brain MRI to evaluate cerebrovascular reactivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brain MRI
Description: both case and control groups received brain MRI to evaluate cerebrovascular reactivity
Study: NCT02437708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REP with L-PRF
Study: NCT02598310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 260mg/m2 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
Study: NCT02508792

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER
Description: Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
Study: NCT00636766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
Study: NCT02437708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: REP